ERBB2 and gastric cancer: To address the unmet need for new therapies to treat HER2-overexpressing breast and gastric cancers, we systemically investigated the combination strategies using inetetamab (Cipterbin) [17,18], a newly marketed anti-HER2 mAb developed by Sunshine Guojian Pharmaceutical Company, in combination with a set of small-molecule antitumor agents in xenograft models.